Ophthalmology. Retina最新文献

{"title":"Re: Griffin et al.: Pneumatic retinopexy for rhegmatogenous retinal detachment outcomes: IRIS Registry (Intelligent Research in Sight) analysis (Ophthalmol Retina. 2025;9:437-443).","authors":"Andrew Mihalache, Marko M Popovic, Rajeev H Muni","doi":"10.1016/j.oret.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.010","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OCT Findings in a Patient with Mild ABCA4 Stargardt Disease.","authors":"James T Kwan, Peter Y Zhao, Michelle C Liang","doi":"10.1016/j.oret.2025.04.013","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.013","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rate and Rationale for Vitrectomy Following Pneumatic Retinopexy.","authors":"Bradley T Smith, M Zia Siddiqui, Gautam Vangipuram, Charles Li, Xuan Peng, Flora Lum","doi":"10.1016/j.oret.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.oret.2025.05.007","url":null,"abstract":"<p><strong>Purpose: </strong>To report the rate and rationale for vitrectomy (PPV) following retinal detachment (RD) repair with pneumatic retinopexy (PnR).</p><p><strong>Design: </strong>Retrospective, nonrandomized, comparative study.</p><p><strong>Participants: </strong>IRIS® Registry (Intelligent Research in Sight) patients undergoing PnR from 04/01/2013 to 12/31/2021.</p><p><strong>Methods: </strong>Billing codes were used to apply inclusion/exclusion and define three groups for comparison following PnR. Group 1 eyes had a non-RD PPV following PnR. Group 2 did not require a surgical procedure following PnR. Group 3 had RD that required surgical repair following PnR.</p><p><strong>Main outcome measures: </strong>Subsequent PPV for indications other than RD repair, follow-up duration and visual acuity (VA).</p><p><strong>Results: </strong>9,488 eyes of 9,401 patients met the study criteria. Mean age was 65 and most were males (60.2%). 9,107 of these eyes were analyzed according to the inclusion/exclusion criteria. Group 1 included 556 eyes, Group 2 included 5,351, and Group 3 included 3,200. In Group 1, PPV alone was performed in 30.8% (171 eyes), internal limiting membrane was removed in 25.7% (143 eyes), and epiretinal membrane was removed in 18.3% (102 eyes). Panretinal or focal endolaser photocoagulation was performed with a PPV in 13.3% (74 eyes) and 11.9% (66 eyes), respectively. Average baseline VA in Group 1 (0.35 logMAR, 20/45) was similar to Group 2 (0.33 logMAR, 20/43). Mean final VA was lower (0.33 logMAR (20/43) versus 0.21 logMAR (20/32), p<0.001), mean follow-up duration was longer (1,556 days versus 1,227, p<0.001), and more were male (63.3% versus 56.1%, p=0.006). Mean follow-up duration was longer than Group 3 (1,401 days, p=0.002) while final VA was similar to Group 3 (0.38 logMAR (20/48), p=0.50). 64.9% (5,907 eyes) were reattached using PnR and 9.4% (556) of these required a non-RD PPV.</p><p><strong>Conclusions: </strong>Nearly one in 10 eyes required a non-RD PPV following reattachment with PnR. VA outcomes were similar to eyes requiring surgical repair for RD. The possible need for PPV after reattachment with PnR should be addressed when counseling patients.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence of Macular Edema in Branch Retinal Vein Occlusion - a Comparison of Aflibercept and Ranibizumab in a Randomized Trial.","authors":"Anna Cullhed Farrell, Manuel Casselholm de Salles, Charlotte Lindberg, David Epstein","doi":"10.1016/j.oret.2025.05.012","DOIUrl":"https://doi.org/10.1016/j.oret.2025.05.012","url":null,"abstract":"<p><strong>Objective: </strong>To prospectively investigate the time to recurrence of macular edema (ME) in patients with branch retinal vein occlusion (BRVO) treated with intravitreal aflibercept or intravitreal ranibizumab injections, and the correlation between subfoveal choroidal thickness (SFCT) at disease onset and the time to edema recurrence.</p><p><strong>Design: </strong>Randomized, double-masked, controlled clinical trial.</p><p><strong>Participants: </strong>One hundred and ten patients with treatment-naïve BRVO and ME presenting between 2018-2021 at St. Erik Eye Hospital, Stockholm, Sweden.</p><p><strong>Methods: </strong>Eligible patients were randomized to receive intravitreal injections with aflibercept 2 mg (Eylea) (n=55) or ranibizumab 0.5 mg (Lucentis) (n=55). ME and SFCT were assessed with optical coherence tomography (OCT). The mean difference in SFCT (diffSFCT) between the study eyes and healthy fellow eyes was calculated. A minimum of three injections were administered monthly until complete resolution of the edema. Thereafter the patients were monitored for edema recurrence. Total follow-up time was 9 months.</p><p><strong>Main outcome measures: </strong>Time to recurrence of ME after the initial edema resolution, number of injections required for the edema to resolve, and the correlation between SFCT at baseline and time to edema recurrence.</p><p><strong>Results: </strong>Mean time to recurrence of ME was significantly longer in the aflibercept group, with a mean time of 10.7±2.9 weeks compared to 8.9±1.5 weeks in the ranibizumab group (p<0.001). There was no difference between the groups regarding the number of monthly injections required to obtain edema resolution, with a mean number of 2.1 injections in each group. Overall, a greater SFCT and diffSFCT at baseline was associated with a shorter time to edema recurrence. When analyzing the diffSFCT by quartiles, the mean time to recurrence was 9.2±1.6 weeks in the top quartile (diffSFCT ≥99 μm) compared to 11.2±3.0 weeks in the bottom quartile (diffSFCT ≤10 μm) (p=0.017).</p><p><strong>Conclusions: </strong>Time to recurrence of ME in BRVO was significantly longer in patients treated with aflibercept compared to those receiving ranibizumab. A greater SFCT and diffSFCT at baseline was associated with a shorter time to edema recurrence, suggesting that these parameters could serve as predictive OCT biomarkers in BRVO.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Collapse of Retinoschisis Due to Formation of Outer Layer Breaks.","authors":"Amreen Qureshi, Shivesh Varma, Daniel Chiu","doi":"10.1016/j.oret.2025.04.014","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.014","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Reattachment of a Total Rhegmatogenous Retinal Detachment.","authors":"Bruno Felipe Oliveira Silva, Victor Bellanda, Rodrigo Jorge","doi":"10.1016/j.oret.2025.04.007","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.007","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marijuana use and failure of initial surgical management of retinal detachment.","authors":"Jeffrey A Brown, Kai R Seely, William E Smiddy, Nicolas A Yannuzzi, Robert O'Brien, Audina M Berrocal, Harry W Flynn, Justin H Townsend","doi":"10.1016/j.oret.2025.05.011","DOIUrl":"https://doi.org/10.1016/j.oret.2025.05.011","url":null,"abstract":"<p><p>In this study, we found that marijuana users had a ∼70% increased rate of failure of initial surgical management of retinal detachment (hazard ratio (HR=1.74; p=0.002). Counseling patients regarding this risk may be beneficial.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Epiretinal Membrane on Anatomical and Visual Outcomes in Patients with Full-Thickness Macular Holes.","authors":"Masanori Iwasaki, Hiroyuki Nakashizuka, Naoki Nezu, Mai Omori, Koji Tanaka, Ryusaburo Mori, Hiroyuki Shimada","doi":"10.1016/j.oret.2025.05.009","DOIUrl":"https://doi.org/10.1016/j.oret.2025.05.009","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the impact of an epiretinal membrane (ERM) on the postoperative outcomes of full-thickness macular hole (MH) repair, focusing on anatomical closure rates, postoperative visual acuity, and recovery of the outer retinal layers.</p><p><strong>Design: </strong>A retrospective cohort study PARTICIPANTS: 605 eyes from 594 patients who underwent MH surgery from 2015 to 2023.</p><p><strong>Methods: </strong>Patients were divided into two groups (MH with ERM [254 eyes] and MH without ERM [351 eyes]). Multiple regression analysis was employed to evaluate surgical outcomes, adjusting for minimum hole size and high myopia in relation to the initial MH closure rate and for preoperative visual acuity and concurrent cataract surgery in relation to postoperative visual acuity at 3 months. In all cases, ERM and internal limiting membrane (ILM) peeling were performed, and the inverted ILM flap cover technique was added at the discretion of the surgeon. Patients with MH-associated retinal detachment, myopic foveoschisis and recurrent or traumatic MH were excluded.</p><p><strong>Main outcome measures: </strong>The initial MH closure rate and postoperative visual acuity at 3 months were evaluated using multiple regression analysis.</p><p><strong>Results: </strong>Our results indicated that ERM did not significantly impact MH closure rates (97.2% vs. 98.3%, p = 0.554), which was consistent with the findings of the multiple regression analysis (r = -0.310, p = 0.666). The inverted ILM flap technique effectively promoted MH closure even in the presence of an ERM (p = 0.021). The MH with ERM group had significantly worse postoperative visual acuity at 3 months (p = 0.004) and significantly lower restoration rates of the outer nuclear layer (64.4% vs. 75.1%, p = 0.006) and external limiting membrane (82.2% vs. 90.1%, p = 0.007).</p><p><strong>Conclusions: </strong>An ERM does not significantly affect anatomical MH closure. The inverted ILM flap technique is effective for MH closure even in the presence of an ERM. An ERM negatively impacted postoperative visual acuity and outer retinal layer restoration.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Treatment Patterns, and Outcomes of Pediatric Non-Infectious Uveitis in the United States: An IRIS® Registry Analysis.","authors":"Ogul E Uner, Phoebe Lin, Laura J Kopplin, Flora Lum, Lynn Liu, Charles Li, Sruthi Arepalli, Debra Goldstein, James T Rosenbaum, Eric B Suhler, Akshay S Thomas","doi":"10.1016/j.oret.2025.05.006","DOIUrl":"https://doi.org/10.1016/j.oret.2025.05.006","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the prevalence, characteristics and treatment patterns of pediatric non-infectious uveitis in the United States (U.S.) DESIGN: Retrospective database study SUBJECTS: Patients with non-infectious uveitis diagnosed and treated at age ≤18 with ≥1 year follow-up identified in the Intelligent Research in Sight (IRIS®) Registry between January 1, 2013 and December 31, 2019.</p><p><strong>Main outcome measures: </strong>Annual prevalence, demographic characteristics, ocular complications, need for ocular surgery, type of anti-inflammatory medications, and difference in visual acuity (VA, logMAR) at presentation, 1 year, and final visit (≥15 months).</p><p><strong>Results: </strong>A total of 5722 pediatric patients (9073 eyes) were identified, representing 2.1% of all non-infectious uveitis patients in the IRIS Registry. Annual prevalence was 11.9 cases per 100 000 patients. Mean (SD) age at diagnosis was 12.5 (4.0) years, 51.3% were female, 56.3% were White, 46.2% had private insurance, and 28.6% had Medicaid. Anatomical subtypes of uveitis included anterior (68.7%), intermediate (13.4%), posterior (6.1%), and panuveitis (10.2%). Mean VA±SD was 0.26±0.37 at diagnosis, 0.18±0.31 at 1 year (p<0.001), and 0.21±0.36 (p<0.001) at final visit with mean (SD) follow-up of 1216 (579) days. 844 (9.3%) eyes had severe vision loss (VA≥1.00) during follow-up. Complications occurred in 1875 (20.7%) eyes, mostly as cataract (10.6%) and macular edema (5.4%), and 479 (5.3%) required ocular surgery. The highest rate of complications and ocular surgeries were seen in patients with panuveitis and posterior uveitis, respectively. Local corticosteroids were used in 5231 (91.4%) and 2467 (43.1%) were started on steroid-sparing agents after diagnosis, most commonly methotrexate (30.9%).</p><p><strong>Conclusion: </strong>Annual prevalence of pediatric non-infectious uveitis in the U.S. per the IRIS Registry is 11.9 cases per 100 000 patients. It represents 2.1% of all non-infectious uveitis. Most patients are White and have anterior uveitis. Unlike adults with uveitis, there is not a strong gender predilection. Mean VA improved significantly 1 year after diagnosis, but 9.3% of eyes had severe vision loss. The anatomic subtype of uveitis significantly affected visual outcomes, complications, and need for ocular surgery. Methotrexate was the most commonly used steroid-sparing immunosuppressive agent. Though complications occurred, patients rarely underwent ocular surgery.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase 3 Trials in Neovascular Age-Related Macular Degeneration.","authors":"Nikolas J S London, Chui Ming Gemmy Cheung, Stephan Michels, Aachal Kotecha, Philippe Margaron, Audrey Souverain, Jeffrey R Willis, Timothy Y Y Lai","doi":"10.1016/j.oret.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.oret.2025.05.004","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the visual and anatomic outcomes by individualized treatment intervals at week 48 in patients with neovascular age-related macular degeneration (nAMD) treated with the dual angiopoietin-2/vascular endothelial growth factor (VEGF)-A inhibitor faricimab in a post hoc analysis of pooled data from TENAYA/LUCERNE.</p><p><strong>Design: </strong>TENAYA/LUCERNE (NCT03823287/NCT03823300) were identically designed, randomized, double-masked, active comparator-controlled, noninferiority phase 3 trials.</p><p><strong>Participants: </strong>Treatment-naïve patients ≥ 50 years of age with nAMD randomized to the faricimab up to every 16 weeks (Q16W; n = 665) arm.</p><p><strong>Methods: </strong>Patients in the faricimab arm received 4 initial Q4W doses through week 12. At weeks 20 and 24, they were assigned to fixed Q8W, Q12W, or Q16W treatment intervals through week 60, based on prespecified central subfield thickness (CST) or best-corrected visual acuity (BCVA) disease activity criteria or presence of new macular hemorrhage, per investigator clinical examination. The primary analysis was at week 48.</p><p><strong>Main outcome measures: </strong>Mean changes from baseline in BCVA and CST through week 48 by treatment interval group.</p><p><strong>Results: </strong>At week 48, the proportion of faricimab-treated patients on each treatment interval was 45.3% (Q16W), 33.4% (Q12W), and 21.2% (Q8W). The baseline patient characteristics were well balanced across faricimab treatment intervals. However, patients assigned to treatment at Q16W and Q12W had less severe disease at baseline versus patients assigned to Q8W. All patients showed sustained BCVA gains and CST reductions through week 48. Mean (95% confidence interval) change from baseline in BCVA was +7.9 letters (6.6, 9.2), +4.0 letters (2.2, 5.7), +5.3 letters (2.4, 8.2); and in CST was -142.9 μm (-156.9, -128.9), -112.5 μm (-131.0, -94.1), and -165.1 μm (-193.8, -136.4) for Q16W, Q12W, and Q8W, respectively.</p><p><strong>Conclusions: </strong>Vision and anatomic improvements were achieved and maintained in all faricimab individualized treatment interval groups, with patients treated at longer intervals having more stable outcomes with fewer injections. The clinically relevant disease activity criteria based on vision or anatomy allowed treatment of patients with nAMD to be rapidly extended after the initial dosing phase while maintaining visual gains through week 48 of TENAYA/LUCERNE.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}